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Abstract Esophageal squamous cell carcinoma (ESCC) has a high mortality rate. To determine the
molecular basis of ESCC development, this study sought to identify characteristic genome-wide
alterations in ESCC, including exonic mutations and structural alterations. The clinical implications
of these genetic alterations were also analyzed. Exome sequencing and verification were performed
for nine pairs of ESCC and the matched blood samples, followed by validation with additional sam-
ples using Sanger sequencing. Whole-genome SNP arrays were employed to detect copy number
alteration (CNA) and loss of heterozygosity (LOH) in 55 cases, including the nine ESCC samples
subjected to exome sequencing. A total of 108 non-synonymous somatic mutations (NSSMs) in
102 genes were verified in nine patients. The chromatin modification process was found to be
enriched in our gene ontology (GO) analysis. Tumor genomes with TP53 mutations were signifi-
cantly more unstable than those without TP53 mutations. In terms of the landscape of genomic
alterations, deletion of 9p21.3 covering CDKN2A/2B (30.9%), amplification of 11q13.3 covering
CCND1 (30.9%), and TP53 point mutation (50.9%) occurred in two-thirds of the cases. These
results suggest that the deregulation of the G1 phase during the cell cycle is a key event in ESCC.
Furthermore, six minimal common regions were found to be significantly altered in ESCC samples
and three of them, 9p21.3, 7p11.2, and 3p12.1, were associated with lymph node metastasis. With
the high correlation of TP53 mutation and genomic instability in ESCC, the amplification of
CCND1, the deletion of CDKN2A/2B, and the somatic mutation of TP53 appear to play pivotal
roles via G1 deregulation and therefore helps to classify this cancer into different genomic subtypes.
These findings provide clinical significance that could be useful in future molecular diagnoses and
therapeutic targeting.
of 3p12.1, and deletion of 9p21.3, and lymph node metastases
in ESCC (P< 0.05).
Results
High heterogeneity of the somatic mutation spectrum in ESCC
To identify the mutation profile in ESCC, exome sequencing
was conducted for tumor and the matched blood samples from
nine ESCC patients (further information about the patients
enrolled in this study is described in Materials and methods,
Figures S1 and S2, and Table S1). As summarized in
Table S2, after quality control, we obtained 31  coverage
on average for the targeted bases and over 93% of all bases
were covered in the targeted regions. The non-synonymous
somatic mutations (NSSMs, present in tumor but absent in
blood samples) identified by exome sequencing were validated
using either Sequenom MassARRAY or Sanger sequencing in
both tumor and blood samples. Overall, 108 NSSMs in 102
genes were verified (Table S3). The number of somatic muta-
tions per tumor sample was highly variable (range 0–36 per
sample, no somatic mutation identified in 3 samples). The most
common type of mutations was missense (80, 74.07%), as com-
pared with other types of mutations such as nonsense muta-
tions (12, 11.11%) and small indels (14, 12.96%). Only one
single splice-site (0.93%) and one read-through mutations
(0.93%) were detected, respectively.
To screen for recurrently-mutated genes, we looked into the
genes with mutations in two or more of the nine tumor samples
(Figure S3). As a result, somatic mutations in TP53 were iden-
tified in five tumor samples (5/9, 55.6%). Both FBXL4 and
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Esophageal cancer is a common type of cancer that is strongly
associated with high mortality and ranks as the sixth leading
cause of death from cancer [1]. Squamous cell carcinoma
and adenocarcinoma are the major types of esophageal cancer.
In the area with high prevalence of esophageal cancer (also
known as the ‘‘esophageal cancer belt”), which stretches from
Northern Iran through the Central Asia to the North Central
China, 90% of all cases are diagnosed as squamous cell carci-
nomas [2–4]. The 5-year survival rate for esophageal squamous
cell carcinoma (ESCC) has been low, but the principal causes
for this disease remain elusive [5–7]. Previous studies have
demonstrated a series of genetic alterations, including a high
somatic mutation rate for TP53 and genomic instability in
numerous chromosomes [8–13]. A comprehensive description
of various types of genetic alterations in ESCC and their cor-
relation with clinical outcome would be a great step forward in
our understanding of the mechanism involved in ESCC devel-
opment, and could be applied to improve the survival rate of
patients.
In this study, we analyzed the ESCC genome by conducting
exome sequencing of nine ESCC sample pairs along with
whole-genome SNP arrays of 55 tumor samples in total. Our
results revealed a very high correlation of TP53 somatic muta-
tion with genomic instabilities in ESCC. Interruption of G1
control by TP53 somatic mutation and copy number alter-
ations (CNAs) was found in over 65% of ESCC cases. Fur-
thermore, for the first time we have identified a significant
correlation between copy number aberrations in three minimal
common regions (MCRs), i.e., amplification of 7p11.2, deletion
DMD were mutated in two tumor samples. DMD was
excluded from our further analysis since this is the largest gene
(measuring 2.4 Mb in human genome according to RefSeq
summary). In general, random mutations may occur more fre-
quently in larger genes, as supported by our observation of
numerous mutations detected in DMD in non-cancerous tis-
sues and in other datasets. TP53 and FBXL4 were subjected
to Sanger sequencing in additional 46 and 120 samples, respec-
tively (TP53 and Panel 2, Figure S2). 50% of the validated
samples (23/46) were found to carry at least one NSSM in
TP53. Totally 26 somatic mutations were identified in these
23 patients, among which 3 patients carried two different
mutations in TP53. These included 19 missense mutations, 5
truncations, and 2 single nucleotide insertions that possibly
result in frameshift. The possible consequences of the 19 mis-
sense mutations were predicted using PolyPhen 2 [14] and
are listed in Table S4. Notably, at least one TP53 mutation
in each of the 23 patients was predicted to be deleterious. Only
one of the 26 somatic mutations in TP53 was reported in
dbSNP, a database of single nucleotide polymorphisms, with
a very low frequency (rs201382018, identified in patient
109596, the allele frequency is 0.02% or 1/5008, accordingly).
With inclusion of the discovery set, somatic mutations in
TP53 were observed in 28/55 of ESCCs (50.90%, Tables S3
and S4). Despite the fact that there was no particular hot spot
identified, most somatic mutations were localized in exons 4–8
of TP53. On the other hand, only two somatic missense muta-
tions were found in FBXL4 in the additional 120 samples of
ESCCs, resulting in a total mutation rate of 3.1% in all the
samples examined.
Furthermore, we conducted Sanger sequencing on the cod-
ing regions of several genes for the validation samples. These
genes were selected based on their known cellular functions
or their roles in various cancers. First, we examined FBXW7,
CD40LG, ANG, and INHBC (Panel 2), WNT2B (Panel 3),
and XRCC2 (Panel 5) as shown in Figure S2, because muta-
tions in these genes were detected in the discovery sample set
(one out of nine patients, Table S3). However, no mutation
was seen in the additional 120 samples. Next, we examined
mutational regions or ‘‘hot spots,” including exon 4 of
AKT1, exons 15 and 19 of BRAF, and exons 9 and 20 of
PIK3CA in 120 cases (Panel 4, Figure S2). We failed to identify
any somatic mutations in the regions examined either.
Taken together, the somatic mutation spectrum showed
very high heterogeneity in ESCC between different tumor sam-
ples. With the exception of TP53, some known cancer-related
genes, including FBXW7, AKT1, BRAF, and PIK3CA, showed
very low mutation rates in our sample population (up to 120
samples).
Mutations involved in chromatin modification process
To explore the biological processes that were interrupted in
ESCC patients, we performed a GO cluster analysis on all
the somatically-mutated genes detected in this study. Ten genes
involved in chromosome organization were significantly
clustered (P= 0.002, Table S5). In particular, seven of them
(identified in five patients), including CHD3, MLL, NASP,
PHF16, SMARCD3, TSPYL2, and UBN1, were further
enriched in the chromatin modification subset (P= 0.005).
Among these seven missense mutations, six mutations were
predicted by SIFT and PolyPhen 2 to have a deleterious effect
on the protein function (Table S3), suggesting that there is a
frequent disruption of the chromatin modification processes
in the pathogenesis of ESCC.
Considering that mutations of chromatin remodeling genes
have been highlighted in several cancer studies [15–19], we then
conducted Sanger sequencing for all the coding regions of
these seven genes in different validation sets (samples for
validation were selected randomly, however, due to limited
volume of DNA samples of each patient, we cannot test all
genes in a single validation set). CHD3, MLL, NASP,
PHF16, and UBN1 were tested in 16 samples (Panel 1),
whereas TSPYL2 and SMARCD3 were tested in 120 samples
(Panel 3) as indicated in Figure S2. However, no additional
mutations in any of the validation samples were detected. This
is most likely due to insufficient number of genes tested, in
view of the fact that there are over 270 genes involved in
chromatin modification, according to GO annotation.
A complex landscape of structural alterations
We used allelic imbalance as an indicator of chromosomal
alterations in ESCC. A total of 107 regions of allelic imbalance
were identified using window sliding, with estimated sizes in
the range of 2–241 Mb (Figure S4). Two major patterns were
found in these nine ESCCs, as illustrated in Figure 1. Tumor
samples from patients 99648, 100036, and 102995 appeared
to suffer few or no chromosomal alterations. On the other
hand, the remaining 6 tumor samples showed many regions
of allelic imbalance, including a few large regions. For
instance, in the tumor sample from patient 101919, 22 allelic
imbalance regions were identified, and the region located at
Chromosome 8 measured 144 Mb, almost covering the
whole chromosome.
Considering the difficulty in determining the boundary and
copy number status in exome sequencing data, we next
performed SNP arrays on 55 tumors and 9 blood samples,
including the 9 tumors and 7 blood samples that were evalu-
ated by exome sequencing, in order to further characterize
the genomic aberrations in ESCC. The fraction of copy
number gain, copy number loss, and copy number neutral loss
of heterozygosity (CNNLOH) were then calculated in order to
estimate the genome instability in each sample.
As shown in Table S6, the fraction of genomic instability,
including copy number gain, copy number loss, and
CNNLOH, ranged from 0.001 to 0.97 (median, 0.557) among
the 55 tumor samples. In total, eight tumor samples showed a
genomic fraction of structural variation of less than 0.05,
including the three tumor samples that showed very low allelic
imbalance in exome sequencing as shown in Figure 1. More-
over, 30 of the 55 tumors (54.5%) had genome-wide alteration
fractions higher than 0.5 (Table S6), suggesting severe genomic
instability in those ESCC samples. In contrast to the tumors,
the median fraction of altered regions in the blood samples
tested was 1.8  104 (in the range of 0–0.06, Table S7),
suggesting very minor, if any, genomic alterations in germ lines
at the scale in this study. This was also demonstrated by an
analysis using cnvPartition (a plug-in for copy number varia-
tion analysis of Genome Studio) (Figure S5 and Table S8).
Regarding the type of genomic alterations in ESCC, the
median fraction of CNNLOH across the entire genome in all
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Figure 1 Allelic imbalance in nine ESCC sample pairs detected using exome sequencing
Bar plots illustrating the minor allele fraction (MAF) of informative SNPs in each exome of blood and tumor samples. The X-axis
indicates the genomic position of each informative SNP on autosomes. The imbalanced regions revealed by window-sliding method are
indicated in red. Apparently tumor samples from patients 99648, 100036, and 102995 were rarely affected by any alteration characterized
by allelic imbalance as seen in the other six tumor samples.
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55 samples was 0.29 (in the range 0–0.67), suggesting frequent
occurrences of acquired uniparental disomy during mitosis.
The median overall genome-wide fractions for copy number
gain and loss were 0.09 (in the range of 0–0.36) and 0.05
(in the range of 6  105–0.38), respectively (Table S6).
Among the 55 tumor samples examined, chromosome 3q
harbored the largest fraction of copy number gain, whereas
chromosome 9p had the largest fraction of copy number loss
and chromosome 17p showed the largest fraction of
CNNLOH (Table S9 and Figure S6).
Both TP53 mutations and CNAs point to cell cycle deregulation
Among the 55 tumor samples analyzed, we identified four
significantly-amplified MCRs containing 34 known genes, as
well as two deleted MCRs covering 19 genes (Figure 2,
Table S10). Among them, MCRs on 11q13.3 and 9p21.3 were
the most significantly amplified and deleted regions, respec-
tively (Q= 2.41  107 and 2.76  108; 17/55 and 17/55,
respectively). This resulted in the amplification of several onco-
genes, including CCND1, FGF3, FGF4, and FGF19, and the
deletion of the tumor suppressor genes CDKN2A and
CDKN2B. In addition, the region with focal amplification in
11q22.1 (Q= 1.25  106, 9/55) contains several cancer-
related genes, including YAP1, which has been reported in
the liver and colorectal cancers [20–22], as well as BIRC2
and BIRC3, which activate the NF-jB signaling pathway
(KEGG pathway database, http://www.genome.jp/kegg/path-
way.html). Additionally, EGFR was amplified in the MCR
of 7p11.2, whereas CADM2, which has been identified as a
tumor suppressor gene in prostate cancer [23,24], was deleted
in the MCR of 3p12.1.
Taken together, we saw a clear grouping in ESCC cases
that were enrolled in this study (Figure 3). About 2/3 of the
samples carried TP53 somatic mutations or focal CNAs that
make a large contribution to damaging cell cycle regulation.
As demonstrated in Figure 4, the most affected nodes are at
p16INK4A/p15INK4B, cyclin D1, and p53, which were caused
by focal deletion of CDKN2A/2B (30.9%), focal amplification
of CCND1 (30.9%), and point mutations in TP53 (50.9%),
respectively. Among the 55 cases examined, 65.45% (36/55)
of the patients carried at least one of these alterations. Consid-
ering the functions of p16INK4A and cyclin D1 in G1 progres-
sion, as well as the role that p53 plays in mitotic check points,
cell cycle regulation appears to be greatly disrupted in tumor
cells of ESCC.
Figure 2 Profiling of genomic deletions and amplifications in 55 ESCC samples
The logR ratios of SNPs were segmented by R‐GADA algorithm [60]. The peaks in red and blue represent the GISTIC Q value (bottom)
and G-score (top) of amplified regions and deleted regions, respectively. The green vertical lines indicate the Q value considered as
significant in the analysis (0.05). Across autosomes 1–22, six MCRs, including 2 deletions and 4 amplifications, were identified (Q< 0.05).
Genes that have been reported to be related to either ESCC or other cancers in previous studies are listed in each MCR. The MCR in the
HLA region of chromosome 6 (asterisk) was not included in this study due to its extremely high degree of polymorphism. Chromosomes
are represented in white (odd-numbered chromosomes) and gray (even-numbered chromosomes) rectangles alternately (with heights in
proportion to the lengths of the respective chromosomes). Positions for centromeres are indicated by the dotted lines. R, probe intensity in
the SNP array; MCR, minimal common region; HLA, human leukocyte antigen.
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ESCCs with TP53 mutations are more genomically unstable
We found a high correlation of TP53 mutations with genome
instability. As depicted in Figure 5, the median fractions of
copy number gain, copy number loss, and CNNLOH in sam-
ples with TP53 mutations were 0.13, 0.11, and 0.35, respec-
tively. These values were significantly higher than those seen
in samples with wild-type TP53, which were 0.05, 0.03, and
0.08, respectively (Mann–Whitney U test P= 1.18  103,
1.43  103, and 9.65  104, respectively). In particular,
75% of the patients with TP53 mutations had severe genomic
instability, while only 33% of the patients with wild-type TP53
had severe genomic instability (P= 0.002).
Chromothripsis likely occurs in one tumor sample
Shattering of chromosomes or chromosome arms was reported
in a fraction of cancer samples, which is believed to be the
driver event in these cases [25]. In the SNP array screen of
55 tumor samples, 42 break points were observed on the chro-
mosome arm 3q in one tumor sample (patient ID 111820; 1/55
or 1.8%), as demonstrated in Figure 6. This suggests the occur-
rence of a genomic instability-generating phenomenon known
as chromothripsis, where tens to hundreds of chromosomal
rearrangements occur in a ‘‘one-off” cellular event [25].
Currently, the clinical consequences of this low-prevalence
genomic event in ESCC remain unknown due to the limited
sample size in our study.
Correlation of genomic alterations with clinical outcome
We also analyzed the association of genomic instability with
clinical information (gender, age, cancer stage and differentia-
tion, tobacco and alcohol consumption, and family cancer his-
tory) and survival status. Patients with severe genomic
instability (P50% of the genome) had a higher percentage
Figure 3 Occurrence of TP53 mutations and CNAs of six MCRs in 55 samples
Each solid bar in the same column represents a single case with color codes as green for point mutation, red for amplification, blue for
deletion, and light gray for no alteration as indicated. The red box indicates 65% (36/55) of samples containing either the TP53
nonsynonymous mutations (in 28 samples), the amplification of 11q13.3 containing CCND1 (in 17 samples), or the deletion of 9p21.3
containing CDKN2A/CDKN2B (in 17 samples). CNA, copy number alteration.
Figure 4 Genomic alterations point to cell cycle G1 deregulation
Both TP53 mutations and CNAs point to G1 deregulation in around two-thirds of ESCC tumor samples. Numbers of samples with TP53
somatic mutation, focal amplification, and focal deletion are labeled in green, red, and blue, respectively.
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of lymph node metastasis than patients with a low (<50% of
the genome) genomic instability (63.3% vs. 36.7%, P= 0.021,
Table S11). In addition, patients with a higher degree of over-
all genomic instability showed poorer survival, although the
difference was not statistically significant (P= 0.083, Fig-
ure S7). Moreover, among the six MCRs identified, three
regions were significantly correlated with lymph node metasta-
sis, including the amplification of 7p11.2 (P= 0.042), deletion
of 3p12.1 (P= 0.030), and deletion of 9p21.3 (P= 0.033)
(Figure 2; Table S12). On the other hand, although non-
synonymous TP53 mutations occurred more frequently, we
observed no correlation between these mutations and clinical
outcome (data not shown).
Discussion
In this study, we performed exome sequencing on nine pairs of
ESCC samples, followed by an analysis of structural alter-
ations using SNP arrays. Due to the relatively low coverage
of exome sequencing, we eliminated all of the false positive
calls through Sequenom or Sanger sequencing verification.
Although we could not avoid certain false negative calls, the
very similar mutation rates of TP53 in the discovery set (5/9)
and validation set (23/46) indicate that our exome sequencing
data are reliable. Moreover, we re-sequenced five exons from
three frequently-mutated cancer genes, AKT1, PIK3CA, and
BRAF, in an additional 120 ESCC samples. The inability to
detect somatic mutations also suggests that high frequency
mutations are seldom seen in ESCC other than in TP53. This
is consistent with the findings of recent genomic studies of
ESCC, in which TP53 was found to be the most frequently
mutated gene (>60% in all studies) [26–29]. Other potential
driver genes defined by these studies mutated only in 20%
samples at most, which were identified as singleton in our
exome sequencing study, for instance somatic frameshift indel
identified in ADAM29 from patient 101919.
Exome sequencing showed limited resolution of structural
alterations, as indicated by the allelic imbalance (Figure 1).
Therefore, to characterize these alterations more precisely,
we conducted a whole-genome SNP array using both the dis-
covery sample set and an additional set of 46 tumors. To
ensure detection of structural alterations in cancer cells, we
set our criterion for a segment containing at least 50 continu-
ous SNPs. In this way, we neglected smaller germline copy
number variations. Using a scanning scale of roughly 150 kb
(one SNP per 3 kb on average), we observed striking evidence
of genomic instability (including copy number gain, loss, and
neutral LOH) than that in the blood samples. As a result,
our SNP array data support that the allelic imbalance in our
exome sequencing data reveals valuable information regarding
structural alterations.
Figure 5 Association of TP53 somatic mutations and genomic instability
Violin plots show the genomic alterations including copy number gain (A, P= 1.18  103), copy number loss (B, P= 1.43  103), and
CNNLOH (C, P= 9.65  104) in ESCC tumors with (TP53 MUT) and without (TP53 WT) TP53 somatic mutations. The overall
fraction of genomic alterations is shown in panel D (P= 1.10  104). CNNLOH, copy number neutral loss of heterozygosity.
Mann–Whitney U test was performed to determine the significant differences.
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Deregulation of cell cycle, especially in G1 phase, plays an
important role in ESCC
A number of in vitro and in vivo experiments have demon-
strated the key role of cell cycle deregulation in tumorigenesis
[30–33]. Many cell cycle-related factors function as either
tumor suppressors or oncogenes [34–36]. The most important
molecule in this process is TP53, whose high mutation rate
has been reported in various types of cancer (IARC TP53
Database, http://p53.iarc.fr/). In this study, we showed strong
new evidence for the old story of cell cycle deregulation in
ESCC. Somatic mutations in TP53 plus two MCRs (deletion
of CDKN2A/2B and amplification of CCND1) point primarily
to cell cycle deregulation in over 65% of the cases examined.
Therefore, TP53 mutations, which disrupt cell cycle check
points at the G1/S and G2/M transitions, and the amplifica-
tion of an oncogene (CCND1) or the deletion of suppressor
genes (CDKN2A/2B) strongly suggest that the disruption of
G1 control is a key event in the development of ESCC
(Figure 4). Although the high rate of TP53 mutation and the
complex DNA alterations have been observed in ESCC and
other cancers [37–41], to our knowledge this is the first analysis
on a large sample size that pinpoints the high frequency of G1
control deregulation caused by genomic alterations in ESCC.
TP53 somatic mutations are correlated with severe genomic
instability
We observed a very high correlation between somatic muta-
tions in TP53 and genomic instability, which has been
Figure 6 Occurrence of chromothripsis in one ESCC tumor sample
The genomic evidence for chromothripsis in one ESCC case (patient ID 111820) is shown by comparison of tumor sample (A) with the
matched blood sample (B). Both B allele frequency and log R ratio on the chromosome arm 3q of the tumor sample demonstrated
numerous break points with limited copy number alterations.
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observed in many previous studies [42–45]. In tumors with a
genomic instability fraction <0.10, only 1 out of 14 samples
had a mutated TP53. Conversely, in samples with fraction
>0.90 for structural alteration, six out of seven samples had
TP53 mutations. One assumption is that the TP53 mutations
and genomic alteration may occur independently and that
TP53 mutations result in a failure to undergo apoptosis in cells
carrying genomic abnormalities [46–48]. On the other hand,
TP53 has also been proposed to be the ‘‘genome guardian”
and mutations in this gene may therefore directly cause other
genomic alterations [33,49]. In our ESCC cases, despite the
high mutation rate of TP53, we found no significant associa-
tion between TP53 mutation and tumor stage, whereas geno-
mic instability correlated with lymph node metastasis.
Therefore, we speculate that the TP53 mutation may occur
early during ESCC development, and one of the consequences
is genome instability, as suggested by many previous studies
[50,51].
Diverse genomic patterns reveal other potential drivers in ESCC
development
In this study, we found 19 samples without any alteration in
cell cycle regulation. Based on their genome instability status,
these cases can further be classified into three types. Two of the
19 samples had severe genomic instability (>0.5) but
contained none of the six MCRs that were identified in other
individuals. Both samples shared focal amplifications at
8p11.21, which encompasses IKBKB, a node in the NF-jB
pathway. Another nine samples had medium genome-wide
instability with alteration fractions of 0.05–0.35. However,
we failed to identify any major common patterns of somatic
mutations or structural alterations in these nine tumors. More
interestingly, the remaining 8 samples showed extremely low
fractions of genomic instabilities (<0.05). Three out of these
8 samples were analyzed by exome sequencing with no somatic
mutations detected. Although we cannot rule out the possibil-
ity of a few false negatives, these examples suggest a special
category of ESCC that carries low numbers of structural vari-
ations. It is therefore, of particular interest to further study
ESCC that has a relatively stable genome. Furthermore, these
findings may provide fundamental insights into the molecular
classification of ESCC.
Other cancer-related mutations and pathway alterations occur
in ESCC
In addition to cell cycle-related copy number gains, several
other genes were also amplified by the 11q13.3 focal change,
such as FGF3/4/19 and CTTN. FGF3/4/19 gene cluster encodes
fibroblast growth factor 3, 4, and 19, members of the FGF
family. Considering their activities in the MAPK and
PI3K-Akt signaling pathways, these amplified factors may also
be involved in mitogenic and cell survival in ESCC. A few
over-expressed genes in cancer are also located in the amplified
region of 11q13.3, including MYEOV (myeloma over
expressed) [52], ORAOV1 (oral cancer over expressed gene 1)
[53], ANO1 in head and neck squamous cell carcinoma [54],
and CTTN in breast cancer and squamous cell carcinomas of
the head and neck [55,56]. Therefore, although CCND1 was
considered as the major player in this MCR, the amplification
of other genes may also contribute to ESCC development.
Furthermore, despite the fact that no common point muta-
tions other than TP53 were found in our study, we observed
one recurrently-mutated gene, FBXL4, in both the discovery
(2/9) and validation sets (2/120). The mutation rate was
3.1% for this gene encoding F-box protein, which is one sub-
unit of the ubiquitin protein ligase complex, implying that
there is disruption in the ubiquitination in some ESCC
samples. These observations call for further investigation of
the ubiquitin-related protein degradation pathway in ESCC
patients.
Clinical significance of our findings
In this study, we observed an association of overall tumor
genomic instability and clinical outcome. In particular, we dis-
covered that three MCRs, amplification of 7p11.2, deletion of
3p12.1, and deletion of 9p21.3, correlated with lymph node
metastasis. Several known cancer-related genes, including
EGFR and CDKN2A/2B, are harbored in these regions.
Additionally, the function of a few other genes, such as
GBE1 and CADM2 in 3p12.1, has not been intensively studied
in cancers and thus deserve further investigation. These
findings suggest that carriers of these MCRs may have poor
disease progression and therefore, detection of these alter-
ations may be helpful in future disease monitoring.
Furthermore, as the heterogeneity has been widely accepted
as a common feature in cancer, a clinic challenge is the thera-
peutic strategy regarding how to deliver proper and individual-
ized treatments. We observed a clear classification in ESCC
cases as the G1 deregulation occurred in 2/3 of the cases exam-
ined. Such a high deregulation frequency in certain pathways
provides promising targeting strategies for future individual-
ized diagnoses and therapeutic development. In particular,
the CDK inhibitors that target early G1 phases may be bene-
ficial for this group of patients.
Conclusions
In this study, we found a 50% prevalence of TP53 mutations
in ESCC, and the somatic mutation of TP53 is highly corre-
lated with genomic instability. Three MCRs are associated
with lymph node metastasis. The amplification of CCND1
and the deletion of CDKN2A/2B, together with TP53 muta-
tions, may play pivotal roles in ESCC by deregulating G1 cell
cycle signaling, which classify this cancer into different groups.
Materials and methods
Sample collection
All ESCC patients enrolled in this study were diagnosed at the
Anyang Cancer Hospital (Henan Province, China) in 2007–
2009. Tumor specimens and paired blood samples were col-
lected from ESCC patients. Written informed consent was
obtained before sample collection. Tumor specimens from
ESCC cases were stored at 70 C immediately following col-
lection. Genomic DNA was purified from tumor samples using
a Biomek 3000 automated workstation with a E.Z.N.A
Mag-Bind Tissue DNA Kit (Omega Bio-Tek, Norcross, GA,
USA), whereas DNA was extracted from blood samples using
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a Whole Blood DNA Extraction Kit (BioTeke, Beijing,
China). DNA quality and quantity were determined using a
NanoDrop 1000 (Thermo Scientific, Wilmington, DE, USA).
Demographic data and patient information, including age,
gender, alcohol and tobacco consumption history, and family
history of cancer, were obtained from patients’ medical
records, as listed in Table S1. Tumor type, tumor cell content,
histological classification, and cancer grade and stage were
reviewed by two pathologists independently. The content of
tumor cells in each sample was over 70%, as shown by hema-
toxylin and eosin staining (Figure S1). The clinical information
for the other 46 tumor samples subjected to SNP array geno-
typing is shown in Table S1. The tumor samples used for
SNP array genotyping and mutational rate validation of
candidate genes are shown in Figure S2. This study was
approved by the Institutional Review Board of the School of
Oncology, Peking University, China.
Exome sequencing data processing
Exome sequencing was performed for nine pairs of ESCC
tumor samples and the matched blood samples. Genomic
DNA libraries were prepared using the Pair-End Genomic
DNA Sample Prep Kit (Illumina, San Diego, CA, USA).
The genomic DNA was sequenced using the Illumina Genome
Analyzer IIx for 75-cycles at BGI, Shenzhen. All original
sequencing tags were converted to the FASTAQ format. To
increase the accuracy and specificity of read mapping and
mutation identification, several pre-processing filters were
applied to the raw sequencing tags. For each sequencing tag,
if two adjacent bases had a Phred quality score <20, then
these two bases and the following bases were trimmed from
the tag, and tags shorter than 35 nt were excluded.
Identification and annotation of the somatic mutations
After the pre-processing quality control, tags were aligned to
the hg18 version of the human genome using the BWA
(Burrows-Wheeler Aligner, version 0.5.8) [57]. Single nucleo-
tide substitutions and small insertion/deletions (indels)
were identified using SAMtools (Utilities for the Sequence
Alignment/Map format) [58]. Under this filtration, the average
number of variants called per sample was 15,957 (12,942–
21,892), and the transition/transversion (Ti/Tv) ratio was
2.74 (on average, ranging 2.40–2.95 for all samples).
In order to identify and further increase the specificity
of somatic mutation calls, we applied the following post-
processing filters: (1) only loci with P10 coverage in both
tumor and normal samples were used for variant calling; (2)
at least 20% of mutant alleles in reads from tumor samples
had a Phred quality scoreP20; and (3) no mutant alleles were
detected in reads from the blood samples.
All NSSMs identified by exome sequencing were subjected
to Sequenom MassARRAY (Sequenom, San Diego, CA,
USA) or conventional Sanger sequencing for validation.
Genomic positions and flanking sequences for all SNVs were
retrieved using the hg18 version of the human genome and
the University of California Santa Cruz (UCSC) genome
annotation database. For Sequenom MassARRAY, PCR
and MassEXTEND primers for multiplexed assays were
designed using the Sequenom MassARRAY Assay Design
3.1 software. The allele-specific extension products of different
masses were quantitatively analyzed using MALDI-TOF mass
spectrometry. Mutation calls were determined using a
MassARRAY Typer 4.0 Analyzer, according to the manufac-
turer’s specifications. For Sanger sequencing, PCR primers
were designed using Primer Premier 5.0 (PREMIER Biosoft,
Palo Alto, CA, USA). The gene ontology (GO) cluster
analysis of all mutated genes was done using the Functional
Annotation Tool of the Database for Annotation, Visualization
and Integrated Discovery (DAVID) [59].
Survey of allelic imbalance
The minor allele fraction (MAF) of each informative SNP
was calculated as a measure of allelic imbalance as shown
below.
MAF ¼ Number of reads containing minor allele
Number of reads containing major allele
An informative SNP was defined as a known heterozygous
SNP at target regions with the coverage of at least 10 distinct
reads in both tumor and blood samples. A difference of MAF
in blood (MAFB) and tumor (MAFT) samples of more than
0.1 was considered to be significant (MAFB MAFTP 0.1).
Window sliding was carried out to estimate the size of the
altered regions. With a window size of 50 SNPs, a window
was considered to be a region undergoing somatic alteration
if more than 70% of the SNPs had a significantly-different
MAF in the tumor and blood samples.
Whole-genome SNP genotyping and data analysis
Whole-genome SNP array for 55 ESCC samples was
performed on Illumina Human OmniZhongHua BeadChips
(Illumina, San Diego, CA, USA). Raw intensity values were
processed to obtain a normalized B allele frequency (BAF)
and a Log R ratio (LRR) for each probe using the Genome
Studio Software V2011.1. LRR values were segmented with
the Genome Alteration Detection Analysis (GADA) [60] using
parameters of T > 10 and segment lengths containing P50
continuous probes. For LOH analysis, the aforementioned
window sliding approach was used with a window size of
100 informative SNPs. A window was considered a LOH, if
more than 80% of the SNPs had a MAF 6 0.9. A segment
was defined either as normal or as having one of 5 types of
alteration status based on the following criteria: (1) normal,
|LRR| < 0.075 and retaining heterozygosity; (2) gain,
LRRP 0.075; (3) loss, LRR 6 0.075; (4) CNNLOH,
|LRR| < 0.075; (5) amplification, LRRP 0.15; and (6) dele-
tion, LRR 6 0.15.
To survey for genome instability, the genomic fractions of
copy number gain, loss, and CNNLOH were estimated by
dividing the number of SNPs undergoing a specific alteration
by the total number of SNPs present in the respective chromo-
some or in the respective sample. To identify common regions
with copy number gain and loss across samples, the Genomic
Identification of Significant Targets in Cancer (GISTIC) algo-
rithm was utilized [61]. Thresholds of LRR were set as 0.15
and 0.15 to allow GISTIC to identify amplifications and
deletions, respectively. Q values of MCRs < 0.05 were defined
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as significant, and 0.99 was used as the confidence level to
determine the region that contained potential driver genes.
Statistical analysis
All statistical analysis was performed using R version 3.1.2 or
SPSS version 19.0 (IBM, Armonk, New York, USA). The
association of overall survival with genomic instability status
was evaluated with Kaplan–Meier curves, and differences
were tested using the log-rank test. Difference was considered
significant with P 6 0.05.
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